Matches in SemOpenAlex for { <https://semopenalex.org/work/W3205307057> ?p ?o ?g. }
- W3205307057 endingPage "1023" @default.
- W3205307057 startingPage "1009" @default.
- W3205307057 abstract "The advent of monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) ushered in a new era of dyslipidemia pharmacotherapy. The first two antibodies targeting PCSK9 (evolocumab, alirocumab) approved by the United States Food and Drug Administration (FDA) provided significant and sustained reductions in atherogenic lipids and a reduced risk of atherosclerotic cardiovascular disease (ASCVD) events. More recently, phase 3 trials of inclisiran-a small interfering RNA-based agent targeting PCSK9-reported similar lipid-lowering effects and preliminary evidence of ASCVD risk reduction, although significant questions remain regarding the extent of benefits across cardiovascular outcomes. We conducted a systematic review and meta-analysis (random-effects model) of the available data on lipid lowering, incidence of atherosclerotic cardiovascular disease (ASCVD) events, and safety of pharmacologic agents targeting PCSK9. A significant and consistent reduction in low-density lipoprotein cholesterol (LDL-C) was observed across all agents (-51% [95% confidence interval {CI}: -61%, -41%]). Despite the impressive reduction in LDL-C, the individual effects on mortality, cardiovascular death, myocardial infarction (MI), and stroke remained nonsignificant. However, a consistent reduction was observed in the composite outcomes of MI, stroke, and cardiovascular death [relative risk {RR} (95% CI): 0.80 (0.73-0.87)] and MI, stroke, unstable angina (requiring revascularization), and cardiovascular death [RR (95% CI): 0.85 (0.74-0.97)]. In terms of safety outcomes, there was no significant difference in severe adverse events, new onset diabetes, neurocognitive disorders, or myalgia. Meanwhile, injection site reaction was more frequent in patients receiving these agents compared to placebo [RR 2.11 (95% CI): 1.26-3.54]. These findings suggest a class effect for favorable lipid changes and a low risk of serious adverse events among pharmacologic agents targeting PCSK9. Although there is compelling evidence that PCSK9-targeting agents reduce the risk of some cardiovascular outcomes, adequately powered studies with longer follow-up may be needed to fully characterize the magnitude of benefits across the cardiovascular spectrum." @default.
- W3205307057 created "2021-10-25" @default.
- W3205307057 creator A5006314392 @default.
- W3205307057 creator A5017348274 @default.
- W3205307057 creator A5021902300 @default.
- W3205307057 creator A5036770035 @default.
- W3205307057 creator A5045688475 @default.
- W3205307057 creator A5061173220 @default.
- W3205307057 creator A5075791833 @default.
- W3205307057 date "2021-10-30" @default.
- W3205307057 modified "2023-10-18" @default.
- W3205307057 title "Meta‐analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD" @default.
- W3205307057 cites W1520609538 @default.
- W3205307057 cites W1966953116 @default.
- W3205307057 cites W1985747185 @default.
- W3205307057 cites W2001328643 @default.
- W3205307057 cites W2010033213 @default.
- W3205307057 cites W2026624820 @default.
- W3205307057 cites W2033451677 @default.
- W3205307057 cites W2036756589 @default.
- W3205307057 cites W2098923148 @default.
- W3205307057 cites W2119605658 @default.
- W3205307057 cites W2125435699 @default.
- W3205307057 cites W2138438666 @default.
- W3205307057 cites W2141898196 @default.
- W3205307057 cites W2170892587 @default.
- W3205307057 cites W2170952317 @default.
- W3205307057 cites W2464924628 @default.
- W3205307057 cites W2478790708 @default.
- W3205307057 cites W2554832534 @default.
- W3205307057 cites W2594441236 @default.
- W3205307057 cites W2596179513 @default.
- W3205307057 cites W2596676407 @default.
- W3205307057 cites W2606366118 @default.
- W3205307057 cites W2746224452 @default.
- W3205307057 cites W2748800769 @default.
- W3205307057 cites W2770626913 @default.
- W3205307057 cites W2899997727 @default.
- W3205307057 cites W2946347198 @default.
- W3205307057 cites W2953269061 @default.
- W3205307057 cites W2973253443 @default.
- W3205307057 cites W3012265841 @default.
- W3205307057 cites W3118615836 @default.
- W3205307057 cites W3183857127 @default.
- W3205307057 doi "https://doi.org/10.1002/phar.2635" @default.
- W3205307057 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34657313" @default.
- W3205307057 hasPublicationYear "2021" @default.
- W3205307057 type Work @default.
- W3205307057 sameAs 3205307057 @default.
- W3205307057 citedByCount "22" @default.
- W3205307057 countsByYear W32053070572021 @default.
- W3205307057 countsByYear W32053070572022 @default.
- W3205307057 countsByYear W32053070572023 @default.
- W3205307057 crossrefType "journal-article" @default.
- W3205307057 hasAuthorship W3205307057A5006314392 @default.
- W3205307057 hasAuthorship W3205307057A5017348274 @default.
- W3205307057 hasAuthorship W3205307057A5021902300 @default.
- W3205307057 hasAuthorship W3205307057A5036770035 @default.
- W3205307057 hasAuthorship W3205307057A5045688475 @default.
- W3205307057 hasAuthorship W3205307057A5061173220 @default.
- W3205307057 hasAuthorship W3205307057A5075791833 @default.
- W3205307057 hasConcept C126322002 @default.
- W3205307057 hasConcept C127413603 @default.
- W3205307057 hasConcept C142724271 @default.
- W3205307057 hasConcept C164705383 @default.
- W3205307057 hasConcept C204787440 @default.
- W3205307057 hasConcept C27081682 @default.
- W3205307057 hasConcept C2776839432 @default.
- W3205307057 hasConcept C2778096610 @default.
- W3205307057 hasConcept C2778114629 @default.
- W3205307057 hasConcept C2778163477 @default.
- W3205307057 hasConcept C2779134260 @default.
- W3205307057 hasConcept C2780072125 @default.
- W3205307057 hasConcept C2780645631 @default.
- W3205307057 hasConcept C2780745583 @default.
- W3205307057 hasConcept C2780902209 @default.
- W3205307057 hasConcept C2780948078 @default.
- W3205307057 hasConcept C43554185 @default.
- W3205307057 hasConcept C44249647 @default.
- W3205307057 hasConcept C500558357 @default.
- W3205307057 hasConcept C71924100 @default.
- W3205307057 hasConcept C78519656 @default.
- W3205307057 hasConcept C82789193 @default.
- W3205307057 hasConceptScore W3205307057C126322002 @default.
- W3205307057 hasConceptScore W3205307057C127413603 @default.
- W3205307057 hasConceptScore W3205307057C142724271 @default.
- W3205307057 hasConceptScore W3205307057C164705383 @default.
- W3205307057 hasConceptScore W3205307057C204787440 @default.
- W3205307057 hasConceptScore W3205307057C27081682 @default.
- W3205307057 hasConceptScore W3205307057C2776839432 @default.
- W3205307057 hasConceptScore W3205307057C2778096610 @default.
- W3205307057 hasConceptScore W3205307057C2778114629 @default.
- W3205307057 hasConceptScore W3205307057C2778163477 @default.
- W3205307057 hasConceptScore W3205307057C2779134260 @default.
- W3205307057 hasConceptScore W3205307057C2780072125 @default.
- W3205307057 hasConceptScore W3205307057C2780645631 @default.
- W3205307057 hasConceptScore W3205307057C2780745583 @default.
- W3205307057 hasConceptScore W3205307057C2780902209 @default.